Axsome Therapeutics Q3 2026 Earnings Preview
Axsome Therapeutics is scheduled to report third-quarter results before market open on Monday, November 2. [[fact:fact-9pdwxe7uy]] The consensus estimate is a loss of $0.64 per share, an improvement of 31.9% year over year. [[fact:fact-tinie3g9x]] The consensus revenue estimate is $249.19 million, up 45.7% year over year. [[fact:fact-unh51j6sy]]
Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say - Zacks Investment Research
Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say - Zacks Investment Research(摘要待生成)
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research(摘要待生成)
Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says - Yahoo Finance
Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says - Yahoo Finance(摘要待生成)
Axsome (AXSM) Q3 2026 Earnings Call Transcript
Axsome (AXSM) Q3 2026 Earnings Call Transcript(摘要待生成)
AXSM: Revenue grew 52% as AUVELITY momentum and pipeline progress strengthened the outlook
AXSM: Revenue grew 52% as AUVELITY momentum and pipeline progress strengthened the outlook TradingView
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
In the 12 months ended September 30, 2026, Axsome Therapeutics generated about $865.3 million in revenue, approximately 54% higher than in the prior period. [[fact-d86izuc14]] Axsome reported a net loss of around $157.3 million over that period. [[fact-b7k7bi2es]] Moderna generated about $2.5 billion in revenue in the 12 months ended September 30, 2026, growing approximately 13.7% over the prior period. [[fact-us2dnf34c]] Moderna recorded a net loss of around $2.8 billion over that period. [[fact-ith9wk6ky]] The article's author considers Axsome the better buy for 2027, citing Moderna's premium valuation and Axsome's revenue growth. [[fact-5htr1lyal]]
Axsome Therapeutics stock hits 52-week low at 123.41 USD By Investing.com - Investing.com Canada
Axsome Therapeutics stock hits 52-week low at 123.41 USD By Investing.com Investing.com Canada
$AXSM stock is down 10% today. Here's what we see in our data. | AXSM Stock News
$AXSM stock is down 10% today. Here's what we see in our data. Quiver Quantitative